GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dawnrays Pharmaceutical (Holdings) Ltd (HKSE:02348) » Definitions » EBIT

Dawnrays Pharmaceutical (Holdings) (HKSE:02348) EBIT : HK$698 Mil (TTM As of Jun. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Dawnrays Pharmaceutical (Holdings) EBIT?

Dawnrays Pharmaceutical (Holdings)'s earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was HK$602 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$698 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dawnrays Pharmaceutical (Holdings)'s annualized ROC % for the quarter that ended in Jun. 2024 was 22.23%. Dawnrays Pharmaceutical (Holdings)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 78.03%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dawnrays Pharmaceutical (Holdings)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 102.28%.


Dawnrays Pharmaceutical (Holdings) EBIT Historical Data

The historical data trend for Dawnrays Pharmaceutical (Holdings)'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dawnrays Pharmaceutical (Holdings) EBIT Chart

Dawnrays Pharmaceutical (Holdings) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 355.42 398.46 538.72 489.99 453.97

Dawnrays Pharmaceutical (Holdings) Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 264.70 237.82 358.26 95.71 602.23

Competitive Comparison of Dawnrays Pharmaceutical (Holdings)'s EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Dawnrays Pharmaceutical (Holdings)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dawnrays Pharmaceutical (Holdings)'s EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dawnrays Pharmaceutical (Holdings)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dawnrays Pharmaceutical (Holdings)'s EV-to-EBIT falls into.


;
;

Dawnrays Pharmaceutical (Holdings) EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$698 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dawnrays Pharmaceutical (Holdings)  (HKSE:02348) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dawnrays Pharmaceutical (Holdings)'s annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=612.788 * ( 1 - 11.71% )/( (2352.103 + 2516.348)/ 2 )
=541.0305252/2434.2255
=22.23 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3962.388 - 460.443 - ( 1166.731 - max(0, 731.672 - 1881.514+1166.731))
=2352.103

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4354.127 - 508.051 - ( 1329.728 - max(0, 706.054 - 2401.278+1329.728))
=2516.348

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Dawnrays Pharmaceutical (Holdings)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1204.462/( ( (1331.414 + max(-70.689, 0)) + (1338.788 + max(416.815, 0)) )/ 2 )
=1204.462/( ( 1331.414 + 1755.603 )/ 2 )
=1204.462/1543.5085
=78.03 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(166.675 + 230.904 + 131.687) - (460.443 + 0 + 139.512)
=-70.689

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(171.733 + 253.694 + 499.439) - (508.051 + 0 + 0)
=416.815

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dawnrays Pharmaceutical (Holdings)'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=697.939/682.403
=102.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dawnrays Pharmaceutical (Holdings) EBIT Related Terms

Thank you for viewing the detailed overview of Dawnrays Pharmaceutical (Holdings)'s EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Dawnrays Pharmaceutical (Holdings) Business Description

Traded in Other Exchanges
N/A
Address
338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
Executives
Fortune United Group Limited 2101 Beneficial owner
Hunwick International Limited 2201 Interest of corporation controlled by you
Keysmart Enterprises Limited 2201 Interest of corporation controlled by you
Iu Pun 2202 Interest of your spouse
Li Tung Ming
Li Kei Ling
Hung Yung Lai
Fmr Llc 2201 Interest of corporation controlled by you
Toyo International Investment Limited
Leung Hong Man
Leung Yiu Sing
Chu Shuet Fong
Lo Mei Sai
Time Lead Investments Limited

Dawnrays Pharmaceutical (Holdings) Headlines

No Headlines